

31 May 2019

## ASX Announcement

# Second Million Dollar Month

We refer to the commentary in the ASX Release of 2 May 2019 entitled Million Dollar Month.

While, PolyNovo has said previously that it does not intend to issue quarterly financial statements, the company would like to inform shareholders it has had its second million-dollar month.

PolyNovo is pleased to announce revenue from BTM sales for the month of May are more than \$1M (May 2018 \$192,410) and greater than the April 2019 revenue.

PolyNovo's CEO, Mr Paul Brennan said "*May sales demonstrate that we are continuing to ramp our sales revenues. Further the size mix and order volumes are demonstrating a wide clinical application across trauma and surgical wounds. The May sales do not yet contain any contribution from Israel, South Africa or India.*"

Further information,  
Paul Brennan  
Chief Executive Officer  
Mobile +61 427 662 317

### About NovoSorb®

NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile. NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn.

### About PolyNovo®

PolyNovo is an Australian based medical device company that designs, develops and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information and market presentations see [www.polynovo.com.au](http://www.polynovo.com.au)